Chest Suite
Empowering breakthroughs in chest care
An AI-powered suite of modular applications that streamline imaging interpretation workflows by automating detection and quantification of pulmonary nodules, standardizing reporting and tracking changes over time. Its AI-power improves diagnostic accuracy, clinical consistency and workflow efficiency.
Book a demo
Discover a New Standard of AI-Powered Care at RSNA 2025
Enhanced efficiency and accuracy in lung cancer diagnosis
Enables more accurate diagnosis with automated detection and characterization of pulmonary nodules, demonstrating high sensitivity1,2 and low false negatives3.
Provides consistent, automated analysis with accurate, quantified measurements of diameters and volumes over time, reducing reading time4.
Drives personalized care with a fully automated measurement tool that highlights and quantifies coronary arteries calcifications providing a coronary calcium score.
Enables better monitoring by comparing previous and current images, calculating growth percentage and volume doubling time.
Strengthen operational resilience and drive innovation at scale
Cloud-native, accessible from anywhere
Automated & standardized reporting
Seamless interoperability, vendor agnostic
Proof in practice Evidence, Experience and Resources
76%
of screen-detected lung cancers were discovered at stage I or II, supporting earlier, more treatable diagnosis1
~87%
Sensitivity for detecting lung nodules on screening CT exams at ≤2 false-positive lesions per scan2
1
Only one missed cancer (0,02%) and four false-positive surgeries across 4,198 CT scans3
~40%
Faster CT nodule reporting time shown by radiologists when aided by AI4
Real voices.
Real impact.
Dr. Samavia Raza
Responsible Radiologist, University Hospital of North Midlands (UK)
Implementing AI into Targeted Lung Health Check has enabled us to deliver lung screening across the country with greater efficiency than would have otherwise been possible. Having AI for these scans increases not only the confidence and pace of the reporter but also reduces stress and burnout potential.
Dr. Sophie Tisi
Respiratory Physician,NHS Lung Cancer Screening Programme
Before the program started, we were seeing most lung cancers being diagnosed at later stages. The data that we now have from the targeted lung health checks is that 75% of the lung cancers they're picking up are early stage—that stage is 1 and 2.
Prof. Sam Hare
Consultant Chest Radiologist, CEO Heart Lung Health
I'm working much faster. I'm reporting far more CT scans in an hour or a day than I ever have, and I'm reporting them more confidently. The AI has made me a better radiologist.
Transforming population health with AI-powered diagnostic screening programs
Explore our visionCould healthcare begin before illness ever shows up? Rather than waiting for patients to experience symptoms, what if care started with prevention, early detection, and access to critical diagnostic tools?
Finding and treating diseases, like cancer, at earlier stages increases survival rates.5 Screening healthy people helps make early detection more possible. By expanding screening for a range of diseases, more people have the chance to stay healthy longer—and this shift has the potential to significantly transform population health.
Population Health Suite of Solutions
Orchestrate and scale high-volume cancer screening and disease assessment programs.
Find out more[2] DeepHealth pivotal study for FDA 510(k) clearance of Lung AI, 14-reader by 300-case MRMC study and standalone testing on 300 screening CT exams. Data on file.
[3] Palmer et al. “Screening benefits and harms; a review of false positives and negatives from the Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Targeted Lung Health Check (TLHC) programme”. Poster abstracts of the 23rd Annual BTOG. Lung Cancer 200S1. 2025.
[4] Hempel et al. “Higher agreement between readers with deep learning CAD software for reporting pulmonary nodules on CT.” Eur J Radiol Open. Aug 2022.
[5] American Cancer Society. Breast Cancer Screening Guidelines, December 2023. Available on the https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html. (Accessed July 16, 2025)
Disclaimers: Chest Suite comprises multiple applications including Veye Lung Nodules, Veye Reporting, DeepHealth Lung AI, DeepHealth Viewer and HealthCCSng. Veye Lung Nodules and Veye Reporting are manufactured by Aidence B.V. and distributed by DeepHealth, Inc. Neither Veye Lung Nodules nor Veye Reporting are FDA cleared for distribution in the US. DeepHealth Lung AI is FDA 510(k) pending. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. in the US. HealthCCSng is manufactured by Nanox AI, Ltd. and distributed by DeepHealth, Inc. DeepHealth Lung AI is 510(k) pending. Any claims made about Chest Suite may reference claims associated with its individual components. Not all products and functionalities are commercially available in all countries